News and Announcements
Startup Advice: Raise Early, Don’t Delay
- Published December 19, 2022 8:15AM UTC
- Publisher Rhori Stein
- Categories Capital Raising Tips
If you’re a founder of a cash-burning business with no path to breakeven don’t delay the raise in the hope that the market sentiment will improve.
Hope isn’t a strategy, and no one can’t predict the future. But when planning cash flow your base case should be pessimistic.
The closer you get to the end of your runway the less likely you are to raise, and if you don’t raise the business will go under.
So start early and have as many investor conversations as possible.
Their feedback will tell you if you can raise in the current climate or not. If it’s the latter, by starting early, you’re maximizing the time that you have to take the drastic action required to survive.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
